Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 78

Results For "Research"

2024 News Found

DGCI grants Emergency Use Authorisation to Gennova mRNA Covid booster vaccine
News | June 21, 2023

DGCI grants Emergency Use Authorisation to Gennova mRNA Covid booster vaccine

The booster vaccine can be administered safely to individuals who have received two doses of either Covaxin or Covishield


Lupin signs MoU with Govt. of Maharashtra to combat rising prevalence of cardiovascular diseases
News | June 21, 2023

Lupin signs MoU with Govt. of Maharashtra to combat rising prevalence of cardiovascular diseases

The partnership aims to prioritize the diagnosis and treatment of these diseases while working to reducing their long-term prevalence


Capex commitment likely to be in the range of Rs. 200-300 Cr: Dr. R. Ananthanarayanan, CEO, Sajjan India
interviews | June 20, 2023

Capex commitment likely to be in the range of Rs. 200-300 Cr: Dr. R. Ananthanarayanan, CEO, Sajjan India

Sajjan India Limited is looking for expansion, both organically and through acquisitions, to achieve the planned growth


Astellas and Cullgen enter inks agreement to advance innovative targeted protein degraders
News | June 19, 2023

Astellas and Cullgen enter inks agreement to advance innovative targeted protein degraders

Cullgen will have the option during the initial stages of clinical development to participate equally in the costs, profits and losses


Laurus Labs signs MOA with IIT Kanpur for novel gene therapy assets
Biotech | June 19, 2023

Laurus Labs signs MOA with IIT Kanpur for novel gene therapy assets

Laurus will also provide funding for the clinical trials and will launch these products in India and emerging markets


Merck completes acquisition of Prometheus Biosciences
News | June 17, 2023

Merck completes acquisition of Prometheus Biosciences

Acquisition delivers industry-leading research capability, and strengthens pipeline with a novel candidate for ulcerative colitis, Crohn’s disease and other autoimmune conditions


Pembrolizumab + Trastuzumab and chemotherapy met primary endpoint as first line of treatment for GEJ
News | June 17, 2023

Pembrolizumab + Trastuzumab and chemotherapy met primary endpoint as first line of treatment for GEJ

Based on a subgroup analysis by PD-L1 expression from KEYNOTE-811, Merck is working with the US FDA to update the current indication for KEYTRUDA in HER2-positive gastric or GEJ adenocarcinoma


Health Ministry to prepare National Action Plan on AMR 2.0
Policy | June 17, 2023

Health Ministry to prepare National Action Plan on AMR 2.0

Convergent action on AMR identified as an important area of intervention


MoS Health addresses TB Health Technologies workshop
News | June 17, 2023

MoS Health addresses TB Health Technologies workshop

Urges Innovators to produce quality products that can be deployed at scale